Yalda Sedaghat
Evotec
5 Papers
12 Citations
Yalda Sedaghat is an academic researcher from Evotec. The author has contributed to research in topics: Gene silencing & Huntington's disease. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
Bryan Zeitler,Steven Froelich,Kimberly Marlen,David A. Shivak,Qi Yu,Davis Li,Jocelynn R. Pearl,Jeffrey C. Miller,Lei Zhang,David Paschon,Sarah J. Hinkley,Irina Ankoudinova,Stephen Lam,Dmitry Guschin,Lexi Kopan,Jennifer M. Cherone,Hoang Oanh B. Nguyen,Guijuan Qiao,Yasaman Ataei,Matthew C. Mendel,Rainier Amora,Richard T. Surosky,Josee Laganiere,B. Joseph Vu,Anand Narayanan,Yalda Sedaghat,Karsten Tillack,Christina Thiede,Annette Gärtner,Seung Kwak,Jonathan Bard,Ladislav Mrzljak,Larry Park,Taneli Heikkinen,Kimmo Lehtimäki,Marie Svedberg,Jenny Haggkvist,Lenke Tari,Miklós Tóth,Andrea Varrone,Christer Halldin,Andrea E. Kudwa,Sylvie Ramboz,Michelle Day,Jyothisri Kondapalli,D. James Surmeier,Fyodor D. Urnov,Philip D. Gregory,Edward J. Rebar,Ignacio Munoz-Sanjuan,H. Steve Zhang +50 more
TL;DR: Improvements in a range of molecular, histopathological, electrophysiological and functional endpoints are demonstrated and support the continued development of an allele-selective ZFP-TF for the treatment of Huntington’s disease.
187
Meso scale discovery-based assays for the detection of aggregated huntingtin.
Wolfgang Reindl,Barbara Baldo,Jana Schulz,Isabell Janack,Ilka Lindner,Markus Kleinschmidt,Yalda Sedaghat,Christina Thiede,Karsten Tillack,Christina Schmidt,Isabell Cardaun,Tom Schwagarus,Frank Herrmann,Madlen Hotze,Georgina F. Osborne,Simone Herrmann,Andreas Weiss,Celina Zerbinatti,Gillian P. Bates,Jonathan Bard,Ignacio Munoz-Sanjuan,Douglas Macdonald +21 more
TL;DR: These novel MSD assays complement the existing MSD platform assays specific for soluble HTT monomers, allowing for a more comprehensive analysis of disease-relevant HTT species in preclinical models of HD.
Identification of REST-Regulated Genes and Pathways Using a REST-Targeted Antisense Approach
TL;DR: The findings suggest that REST may be an important target for neurodegenerative diseases like Huntington's disease, is also involved in the regulation of a broad range of additional cellular pathways, and that the antisense approach is a viable strategy for selectively modulating REST activity in vivo.
12
Patent
Modulation of re1 silencing transcription factor expression
Yalda Sedaghat,Breet P. Monia,Huynh-Hoa Bui +2 more
- 10 Sep 2010
TL;DR: In this article, methods for treating or preventing Huntington's Disease in an individual in need thereof by decreasing REST expression and/or increasing DMN1, BDNF, and synapsin1 expression are described.
3
Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
Nikisha Carty,Nadege Berson,Karsten Tillack,Christina Thiede,Diana Scholz,Karsten Kottig,Yalda Sedaghat,Christina Gabrysiak,George J. Yohrling,Heinz Von Der Kammer,Andreas Ebneth,Volker Mack,Ignacio Munoz-Sanjuan,Seung Kwak +13 more
TL;DR: A high-content histological approach is used to precisely monitor changes in HTT expression and characterize deposition dynamics of mHTT protein inclusion bodies in the recently characterized zQ175 knock-in mouse line to demonstrate successful application of this platform to quantitatively assess target engagement and outcome on a cellular basis.